Nippon Kayaku Co., Ltd. (NPKYF)
ÜberbewertetFundamental
66
Kurs
$2083.50
Marktkapitalisierung
$307.91B
Teil 1 · Was das Unternehmen wert ist
Übersicht
Nippon Kayaku was founded in 1916 as Japan's first industrial explosives maker and has since turned its chemistry expertise into three unrelated businesses: specialty chemicals such as epoxy resins and dyes, pharmaceuticals including anti-cancer and cardiovascular drugs, and automotive safety components — airbag inflators and micro gas generators sold to seatbelt and airbag makers worldwide. It no longer sells explosives as a core line; that heritage lives on mainly in its name.
Wie das Geld verdient wird
Each business earns money in a different way. Fine chemicals sell to electronics, textile and agrochemical manufacturers as industrial inputs priced on volume and specification. Life sciences revenue comes from drug sales, largely covered by national health insurance systems, with pricing set through negotiation and regulatory approval cycles rather than open competition. Mobility and imaging revenue comes from supplying safety components under long-term contracts with automakers and their tier-one suppliers.
Umsatz nach Segment
Airbag inflators and micro gas generators for automotive safety systems, plus imaging-related chemical products — the largest business domain.
Epoxy resins, UV-curable resins, dyes and electronic materials sold to industrial manufacturers.
Prescription pharmaceuticals, including anti-cancer, cardiovascular and anti-inflammatory drugs.
Wettbewerbsvorteil
Wechselkosten · SchmalAutomakers qualify safety components like airbag inflators through lengthy testing before they go into a vehicle program, so once Nippon Kayaku is designed into a platform it tends to stay there for the life of that model. The same is not true across its other two businesses, where chemicals and drugs face more open competition, which is why the advantage is narrow rather than covering the whole company.
Was die Nachfrage antreibt
Mäßig zyklischThe three businesses pull in different directions: pharmaceutical demand is largely defensive, since patients keep needing medication regardless of the economy, while fine chemicals and automotive safety components track industrial and vehicle production, which slow in downturns. The blend leaves the group somewhere between the two extremes rather than firmly cyclical or firmly defensive.
Die Argumente dafür
Buyers argue that spreading revenue across defensive pharmaceuticals, industrial chemicals and automotive safety components gives Nippon Kayaku more balance than a single-industry supplier, and that its long history as a qualified airbag-inflator supplier makes that business hard for a new entrant to displace.
Die Argumente dagegen
Sellers fear that running three unrelated businesses under one roof dilutes management focus and makes it harder for investors to value the company against single-industry peers, and that two of the three segments remain exposed to the same automotive and industrial production cycle at the same time.
Written by the editors, published on 18. August 2026
Direct competitors
Who this company fights with for the same customers
Generated on 19. September 2026 with claude-haiku-4-5 — shared with all users
Another Japanese chemical group that, like Nippon Kayaku, turns pyrotechnic know-how into airbag inflators and micro gas generators sold to the same global car makers and safety-system integrators.
The largest maker of automotive passive safety systems, it produces its own inflators and seatbelt pretensioner gas generators and bids for the same carmaker programmes as Nippon Kayaku's Safety Systems segment.
A major supplier of airbag modules and inflators (the former Takata business, now under Ningbo Joyson) competing for the same airbag and seatbelt contracts with car makers in Asia, Europe and North America.
Competes head-on in epoxy materials for semiconductor encapsulation, selling molding compounds and resins to the same chip packaging and assembly customers.
Supplies epoxy encapsulation materials for semiconductor packages and power modules, addressing the same electronic-materials customers as Nippon Kayaku's functional chemicals business.
Bilanz & Liquidität
Umsatz
$247.90B
Letzte 12 Monate bis zum zuletzt gemeldeten Quartal — Schätzung aus Kennzahlen je Aktie
Nettogewinn
$25.30B
Letzte 12 Monate bis zum zuletzt gemeldeten Quartal — Schätzung aus Kennzahlen je Aktie
Freier Cashflow
-
Gesamtes Eigenkapital
$276.68B
Gesamtverbindlichkeiten
$68.18B
Current Ratio
2.71
Zinsdeckungsgrad
-
Schulden/EBITDA
1.66
Gewinn je Aktie
Umsatz & Nettogewinn
Freier Cashflow
Ertragsaufschlüsselung
Historische Aufstellung
Margen im Zeitverlauf
Verschuldung im Zeitverlauf
Wie schwer die Schulden wiegen
Wachstumsraster
Wachstum — Umsatz
Innerer-Wert-Schätzung
Innerer Wert
$1564.46
Aktueller Kurs
$2083.50
Sicherheitsmarge
-33.2%
Innerer-Wert-Spanne
$1289.98 - $1838.94
Streubreite zwischen den verwendeten Bewertungsmethoden, kein statistisch kalibriertes Konfidenzintervall.
Bewertungsmethoden
Bewertungskennzahlen
P/E-Verhältnis
12.01
ROE
8.9%
P/B-Verhältnis
1.10
P/FCF
-
Bruttomarge
30.3%
ROIC
5.8%
Rentabilitäts-Radar
Wertschöpfung (Wettbewerbsvorteil)
ROIC
5.8%
WACC
7.6%
ROIC − WACC
-1.8 pp
Der ROIC liegt unter den Kapitalkosten: Das Unternehmen vernichtet für jeden investierten Dollar Wert.
Fundamentalanalyse-Kriterien
Bestanden (14)
- ROIC 5.8%
- Gross Margin 30.3%
- P/B Ratio 1.10
- Debt/Equity ratio
- Operating Margin 9.5%
- Current Ratio
- Debt/EBITDA
- Price below Graham Number
- ROE 9.6%
- Revenue Growth 5Y 6.9%
- Analyst Consensus 80% Buy
- Earnings Surprise avg 37.3%
- PEG Ratio 0.68
- Net Margin Trend 17.0% vs 5.1%
Nicht bestanden (3)
- Price CAGR 3.66%
- DCF valuation (Unknown)
- Piotroski F-Score 0/9
Nicht verfügbar (10)
- EPS data insufficient
- P/FCF NaN
- Dividend Payout NaN%
- Positive Free Cash Flow
- CapEx intensity
- Interest Coverage
- Return on Tangible Assets
- Low reliance on intangibles
- Earnings Quality (OCF/Net Income)
- Share Dilution (missing shares data)
Piotroski F-Score
Ernsthafte finanzielle Bedenken
Gewinnqualität
Niedrige Qualität: Rechnungslegung prüfen
Aktienverwässerung
Aktienrückkäufe. Aktionärsfreundlich
Institutionelle Beteiligungen
Für dieses Unternehmen liegen keine institutionellen Meldungen vor.
Unternehmensführung
Führungsteam
| Name | Position | Alter |
|---|---|---|
| Mr. Shigeyuki Kawamura | President, CEO & Representative Director | 62 |
| Mr. Tsutomu Kawamura | General Manager of Finance & Accounting Division | - |
| Yasuhito Kato | MD of Technology & Director | 60 |
| Ichio Kohinata | General Manager of Legal Affairs Division | - |
| Shinji Inoue | Senior Executive Officer of planning, Corp. Communication & Accounting and Director | 59 |
| Makoto Takeda | MD of Human Resource & Director | 61 |
| Hiroshi Shimada | Senior MD, Head of Pharmaceuticals Group & Director | 60 |
| Hideyuki Yuya | MD & Head of Polatechno Group | - |
| Shigehide Kagaya | Head of Catalysts Group, Fine Chemicals Business Unit | - |
| Yoshiki Akatani | Managing Director of Fine Chemicals Business Area | - |
Prüfungsrisiko
1
Vorstandsrisiko
9
Vergütungsrisiko
1
Aktionärsrechterisiko
1
Teil 2 · Der Preis und der Einstiegszeitpunkt
Dieser Teil sagt nicht, ob das Unternehmen etwas taugt: Er hilft bei der Wahl des Kaufzeitpunkts, nachdem die Fundamentaldaten überzeugt haben. Enthalten: technische Analyse, Potenzial, historische Drawdowns, Gamma-Exposure.
Latest News
Recent headlines for NPKYF, sourced from Markets Gazette.